Investigation Launched by Pomerantz Law Firm for Cybin Inc. Investors Amid Allegations of Securities Fraud

Investigation of Cybin Inc. by Pomerantz Law Firm

New York, October 3, 2025 – A wave of concern has been stirred within the investment community as Pomerantz LLP announces its investigation into potential claims on behalf of shareholders of Cybin Inc. (NYSE: CYBN). This scrutiny arises amid serious allegations of securities fraud and other unlawful practices possibly orchestrated by the company's officers and directors.

The point of contention began on September 2, 2025, when Cybin disclosed a major leadership change that has raised eyebrows about the company's governance. Doug Drysdale, the Chief Executive Officer, announced his resignation, a move that reverberated throughout the market, leading to a dramatic decline in stock value. On that day alone, shares dropped by $1.24, equating to a 16.58% plunge, closing at $6.24 per share. This sharp decline has prompted investors to reevaluate their positions and, in many cases, seek legal recourse for potential losses incurred during this volatile period.

Pomerantz LLP has been at the forefront of the legal battle against corporate misconduct and has a rich history dating back over 85 years. Their steadfast commitment to fighting securities fraud and breaches of fiduciary duty has made them one of the most respected firms in the arena of corporate and securities class action litigation. Founded by Abraham L. Pomerantz, a pioneer in the field, the firm's ability to recover substantial damages for investors has established them as a beacon of hope for many who feel wronged by corporate leaders.

The investigation by Pomerantz will focus on whether Cybin's management was aware of any critical information regarding the company’s future that could have impacted stock prices before the public announcement was made. Such circumstances often indicate deceptive practices that violate federal securities laws.

What Investors Should Know
Investors of Cybin Inc. are encouraged to monitor this situation closely, as Pomerantz LLP has called upon individuals to reach out if they believe they have been adversely affected by the actions of the company's leadership. Should sufficient evidence of wrongdoing be discovered, a class action suit may be forthcoming, affording investors the option to join in the legal action against Cybin.

For those looking to connect with Pomerantz LLP, Danielle Peyton is the primary contact for inquiries, and she has made herself readily available to discuss any questions or concerns that investors may have regarding their potential claims.

In the world of investing, particularly in sectors as volatile as biotech, the stakes can be incredibly high. Corporate transparency and accountability are paramount in maintaining investor trust. As this investigation unfolds, Cybin Inc. will undoubtedly find itself under rigorous examination, not only by legal professionals but also by the wider investing public eager for clarity amid uncertainty.

For further information about joining the class action or more details regarding the investigation, interested parties should contact Danielle Peyton directly at [email protected] or call 646-581-9980, ext. 7980.

As this situation progresses, stakeholders will need to stay informed and prepared to make necessary adjustments to their investment strategies based on the developments surrounding Cybin Inc. and its leadership transition.

With ongoing investigations and potential legal implications looming over Cybin, investors should remain vigilant as this crucial chapter in the company’s history continues to unfold.